<DOC>
	<DOCNO>NCT00312663</DOCNO>
	<brief_summary>Phase I/II Trial Malaria Vaccine , FMP011/AS01B , Adults Living United States America .</brief_summary>
	<brief_title>Phase I/II Trial Malaria Vaccine Adults Living United States America</brief_title>
	<detailed_description>- Controlled challenge , Phase I/IIa WRAIR study . - Healthy , malaria-naive adult age 18 - 50 year . - 2 group , 5 subject group A ( 10µg dose ) 15 subject group B ( 50µg dose ) . - Control : none immunization phase ; infectivity control challenge rechallenge phase . Six infectivity control per day challenge enrol challenge phase , 3 alternate available challenge need . - Vaccination schedule 0 , 1 month . - Challenge 15 subject Group B . - Contingent upon short term efficacy , rechallenge initially protect subject 6 month ( +/- 2 month ) second dose vaccine . - Self-contained study . - Duration study , per subject : approximately 15 month ( screen , enrollment , vaccination , challenge rechallenge ) . - Data collection do onsite .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male nonpregnant female 18 50 year age ( inclusive ) time screen . Written inform consent obtain subject screening procedure . Free obvious health problem establish medical history clinical examination enter study . * Available participate duration study ( approximately 15 month ) . If subject female , must currently use birth control , must surgically sterilize , must least 1year post menopausal . Pass comprehension assessment test . Prior receipt investigational malaria vaccine . Use investigational nonregistered drug vaccine study vaccine ( ) within 28 day precede first dose study vaccine , plan use study period . Administration chronic immunosuppressant immune modify drug within six month vaccination . Chronic use antibiotic antimalarial effect . Planned administration/ administration vaccine foreseen study protocol within 30 day first dose vaccine ( ) . History use antimalarial medication within 60 day prior vaccination . Any history malaria . Known exposure malaria within previous 12 month . Planned travel malarious area study period . Any confirm suspected immunosuppressive immunodeficient condition , include HIV infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Chronic active neurologic disease include seizure , include single febrile seizure child . History splenectomy . Acute disease time enrollment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Personal history autoimmune disease subject describe firstdegree relative clearly document autoimmune disease . Seropositive hepatitis B surface antigen . Seropositive Hepatitis C virus ( antibody HCV ) . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan . administration study period Pregnant lactate female . Suspected known current alcohol abuse define American Psychiatric Association DSM IV . Chronic active intravenous drug use . History severe reaction mosquito bite define anaphylaxis . Female intend become pregnant study . Any history anaphylaxis reaction vaccination . A clinical history sickle cell disease sickle cell trait . Any significant finding opinion investigator would increase risk adverse outcome participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Phase I/II</keyword>
	<keyword>Malaria</keyword>
	<keyword>Liver Stage Antigen -1</keyword>
	<keyword>Falciparum Malaria Protein -11</keyword>
	<keyword>AS01B</keyword>
	<keyword>adjuvant</keyword>
</DOC>